JP2024504136A - 「新規な二環式ペプチド」 - Google Patents

「新規な二環式ペプチド」 Download PDF

Info

Publication number
JP2024504136A
JP2024504136A JP2023543460A JP2023543460A JP2024504136A JP 2024504136 A JP2024504136 A JP 2024504136A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2023543460 A JP2023543460 A JP 2023543460A JP 2024504136 A JP2024504136 A JP 2024504136A
Authority
JP
Japan
Prior art keywords
amino acid
bicyclic
alanine
peptidomimetic
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504136A5 (https=
JPWO2022155704A5 (https=
Inventor
ラオ スダー
Original Assignee
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900114A external-priority patent/AU2021900114A0/en
Application filed by ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Publication of JP2024504136A publication Critical patent/JP2024504136A/ja
Publication of JP2024504136A5 publication Critical patent/JP2024504136A5/ja
Publication of JPWO2022155704A5 publication Critical patent/JPWO2022155704A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023543460A 2021-01-19 2022-01-19 「新規な二環式ペプチド」 Pending JP2024504136A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021900114A AU2021900114A0 (en) 2021-01-19 Novel bicyclic peptipes
AU2021900114 2021-01-19
PCT/AU2022/050023 WO2022155704A1 (en) 2021-01-19 2022-01-19 Novel bicyclic peptides

Publications (3)

Publication Number Publication Date
JP2024504136A true JP2024504136A (ja) 2024-01-30
JP2024504136A5 JP2024504136A5 (https=) 2025-01-27
JPWO2022155704A5 JPWO2022155704A5 (https=) 2025-01-27

Family

ID=82548163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543460A Pending JP2024504136A (ja) 2021-01-19 2022-01-19 「新規な二環式ペプチド」

Country Status (9)

Country Link
US (1) US20240117005A1 (https=)
EP (1) EP4281486A4 (https=)
JP (1) JP2024504136A (https=)
KR (1) KR20230146025A (https=)
CN (1) CN117062842A (https=)
AU (1) AU2022209878A1 (https=)
CA (1) CA3208598A1 (https=)
IL (1) IL304545A (https=)
WO (1) WO2022155704A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121108243A (zh) * 2025-01-03 2025-12-12 中国药科大学 一种非核糖体多肽化合物及其合成基因簇bnp37和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) * 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2018537965A (ja) * 2015-10-30 2018-12-27 アフィボディ・アーベー Pd−l1に対して親和性を有する新規ポリペプチド
WO2019136531A1 (en) * 2018-01-15 2019-07-18 University Of Canberra Proteinaceous molecules and uses therefor
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトpd−l1結合性ペプチド
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10585100B2 (en) * 2015-04-30 2020-03-10 Kyoto University Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077062A2 (en) * 2003-02-27 2004-09-10 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP2018537965A (ja) * 2015-10-30 2018-12-27 アフィボディ・アーベー Pd−l1に対して親和性を有する新規ポリペプチド
JP2020502238A (ja) * 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2019136531A1 (en) * 2018-01-15 2019-07-18 University Of Canberra Proteinaceous molecules and uses therefor
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトpd−l1結合性ペプチド
WO2020128527A1 (en) * 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DU W ET AL.: "KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation", CELL DEATH & DIFFERENTIATION, vol. 28, no. 4, JPN6025050831, 2 November 2020 (2020-11-02), pages 1284 - 1300, ISSN: 0005754003 *
SATELLI A ET AL.: "Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells", SCIENTIFC REPORTS, vol. vol.6, 28910, JPN6025050832, 1 July 2016 (2016-07-01), ISSN: 0005754004 *

Also Published As

Publication number Publication date
EP4281486A4 (en) 2025-01-08
US20240117005A1 (en) 2024-04-11
CA3208598A1 (en) 2022-07-28
WO2022155704A1 (en) 2022-07-28
IL304545A (en) 2023-09-01
EP4281486A1 (en) 2023-11-29
AU2022209878A1 (en) 2023-09-07
CN117062842A (zh) 2023-11-14
KR20230146025A (ko) 2023-10-18

Similar Documents

Publication Publication Date Title
US20250002567A1 (en) Anti-complement factor c1q fab fragments and uses thereof
US7071300B2 (en) IGF antagonist peptides
EP3054973B1 (en) Tm4sf1 binding proteins and methods of using same
US20190092822A1 (en) BH4 Stabilized Peptides And Uses Thereof
AU2019207534A1 (en) Proteinaceous molecules and uses therefor
US20110224133A1 (en) Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
JP2024504136A (ja) 「新規な二環式ペプチド」
JP5475406B2 (ja) Gbs毒素受容体
KR20040031031A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
JP2025527370A (ja) ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤
WO2023077188A1 (en) Proteinaceous molecules and uses therefor
CA3006092C (en) Anti-complement factor c1q fab fragments and uses thereof
US7589185B2 (en) Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis
US20200282010A1 (en) Immunogenic compositions and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313